Evaluating the biological variability of blood‐based biomarkers for use in clinical trials

Blood‐based biomarkers offer the possibility of inexpensive, minimally invasive, and accessible diagnostic tools for Alzheimer’s Disease (AD). In the context of clinical trials, these biomarkers hold promise for subject stratification and monitoring the effects of therapeutic interventions. The day‐to‐day variability of these measures must be robustly characterized to determine which blood‐based biomarkers would be the most sensitive for detecting treatment‐related responses. In this study we evaluate biomarker performance in plasma and identify the most reliable candidates for clinical trials.